Do analysts rate XCUR or BYSI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, XCUR or BYSI?

BeyondSpring has higher revenue and earnings than Exicure. BeyondSpring is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 15.07 -$4.95M -$1.32 N/A BeyondSpring $1.75M 14.26 -$1.01M -$0.12 N/A

Is XCUR or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% BeyondSpring N/A N/A -28.88%

Do analysts rate XCUR or KYNB?

Kyntra Bio has a consensus target price of $36.80, suggesting a potential upside of 526.92%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has preferable earnings & valuation, XCUR or KYNB?

Kyntra Bio has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 15.07 -$4.95M -$1.32 N/A Kyntra Bio $6.44M 3.69 $183.45M $45.30 0.13

Is XCUR or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Exicure's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% Kyntra Bio 2,199.13% N/A -47.27%

Do analysts prefer ATOS or XCUR?

Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 694.27%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATOS or XCUR more profitable?

Atossa Genetics' return on equity of -102.99% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Exicure N/A -237.91% -61.98%

Do analysts recommend XCUR or NXTC?

NextCure has a consensus price target of $19.00, indicating a potential upside of 202.55%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings & valuation, XCUR or NXTC?

Exicure has higher revenue and earnings than NextCure. Exicure is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 15.07 -$4.95M -$1.32 N/A NextCure N/A N/A -$55.84M -$8.70 N/A

Is XCUR or NXTC more profitable?

NextCure's return on equity of -154.62% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% NextCure N/A -154.62% -100.19%

Do analysts rate XCUR or JSPR?

Jasper Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 1,379.69%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29

Is XCUR or JSPR more profitable?

Exicure's return on equity of -237.91% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% Jasper Therapeutics N/A -884.17% -143.83%

Exicure (XCUR) Competitors

$1.15 +0.06 (+5.50%)

Closing price 10/13/2026 03:59 PM Eastern

Extended Trading

$1.18 +0.03 (+2.61%)

As of 10/13/2026 06:40 PM Eastern

Compare

XCUR vs. BYSI, KYNB, ATOS, NXTC, and JSPR

Should you buy Exicure stock or one of its competitors? Exicure's main competitors and comparable companies include BeyondSpring (BYSI), Kyntra Bio (KYNB), Atossa Genetics (ATOS), NextCure (NXTC), and Jasper Therapeutics (JSPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Exicure compare to BeyondSpring?

Exicure (NASDAQ:XCUR) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

42.8% of Exicure shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Exicure has a beta of 3.64, meaning that its stock price is 264% more volatile than the broader market. Comparatively, BeyondSpring has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
BeyondSpring	N/A	N/A	-28.88%

In the previous week, Exicure and Exicure both had 2 articles in the media. Exicure's average media sentiment score of 1.41 beat BeyondSpring's score of 0.61 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
BeyondSpring	Positive

BeyondSpring has higher revenue and earnings than Exicure. BeyondSpring is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	15.07	-$4.95M	-$1.32	N/A
BeyondSpring	$1.75M	14.26	-$1.01M	-$0.12	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Exicure and BeyondSpring tied by winning 5 of the 10 factors compared between the two stocks.

How does Exicure compare to Kyntra Bio?

Exicure (NASDAQ:XCUR) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Kyntra Bio has a net margin of 2,199.13% compared to Exicure's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
Kyntra Bio	2,199.13%	N/A	-47.27%

Kyntra Bio has a consensus target price of $36.80, suggesting a potential upside of 526.92%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Kyntra Bio had 2 more articles in the media than Exicure. MarketBeat recorded 4 mentions for Kyntra Bio and 2 mentions for Exicure. Exicure's average media sentiment score of 1.41 beat Kyntra Bio's score of 0.56 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Kyntra Bio	Positive

Exicure has a beta of 3.64, meaning that its stock price is 264% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Kyntra Bio has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	15.07	-$4.95M	-$1.32	N/A
Kyntra Bio	$6.44M	3.69	$183.45M	$45.30	0.13

42.8% of Exicure shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Kyntra Bio beats Exicure on 11 of the 15 factors compared between the two stocks.

How does Exicure compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 694.27%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure has higher revenue and earnings than Atossa Genetics. Exicure is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Exicure	$500K	15.07	-$4.95M	-$1.32	N/A

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Atossa Genetics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Exicure has a beta of 3.64, meaning that its stock price is 264% more volatile than the broader market.

Atossa Genetics' return on equity of -102.99% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Exicure	N/A	-237.91%	-61.98%

In the previous week, Atossa Genetics had 1 more articles in the media than Exicure. MarketBeat recorded 3 mentions for Atossa Genetics and 2 mentions for Exicure. Exicure's average media sentiment score of 1.41 beat Atossa Genetics' score of 0.82 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
Atossa Genetics	Positive
Exicure	Positive

Summary

Exicure beats Atossa Genetics on 8 of the 13 factors compared between the two stocks.

How does Exicure compare to NextCure?

Exicure (NASDAQ:XCUR) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

NextCure's return on equity of -154.62% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
NextCure	N/A	-154.62%	-100.19%

Exicure has a beta of 3.64, suggesting that its share price is 264% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

NextCure has a consensus price target of $19.00, indicating a potential upside of 202.55%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Exicure has higher revenue and earnings than NextCure. Exicure is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	15.07	-$4.95M	-$1.32	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

42.8% of Exicure shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Exicure and Exicure both had 2 articles in the media. Exicure's average media sentiment score of 1.41 beat NextCure's score of 0.27 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
NextCure	Neutral

Summary

Exicure beats NextCure on 8 of the 12 factors compared between the two stocks.

How does Exicure compare to Jasper Therapeutics?

Exicure (NASDAQ:XCUR) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, Jasper Therapeutics had 2 more articles in the media than Exicure. MarketBeat recorded 4 mentions for Jasper Therapeutics and 2 mentions for Exicure. Exicure's average media sentiment score of 1.41 beat Jasper Therapeutics' score of 0.36 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Jasper Therapeutics	Neutral

Exicure has a beta of 3.64, indicating that its stock price is 264% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market.

Exicure's return on equity of -237.91% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
Jasper Therapeutics	N/A	-884.17%	-143.83%

Jasper Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 1,379.69%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

42.8% of Exicure shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 3.9% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Exicure has higher revenue and earnings than Jasper Therapeutics. Exicure is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	15.07	-$4.95M	-$1.32	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

Summary

Exicure beats Jasper Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Exicure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XCUR vs. The Competition

Export

Metric	Exicure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.14M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	9.98	195.99	19.34
Price / Sales	15.07	1,149.11	562.25	81.55
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.85	16.95	10.71	6.03
Net Income	-$4.95M	-$22.69M	$3.50B	$380.34M
7 Day Performance	12.75%	-4.44%	-2.90%	-2.32%
1 Month Performance	-16.06%	-12.51%	-7.37%	-5.29%
1 Year Performance	-77.45%	7.77%	3.05%	-2.94%

Exicure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XCUR Exicure	0.9897 of 5 stars	$1.15 +5.5%	N/A	-77.6%	$7.14M	$500K	N/A	50	Positive News Short Interest Decrease Gap Up
BYSI BeyondSpring	0.3094 of 5 stars	$0.64 -6.9%	N/A	-64.5%	$26.50M	$1.75M	N/A	44
KYNB Kyntra Bio	3.2536 of 5 stars	$6.13 +2.9%	$37.25 +507.7%	N/A	$24.83M	$6.44M	0.14	570	News Coverage Analyst Forecast
ATOS Atossa Genetics	2.1454 of 5 stars	$2.46 +0.4%	$20.33 +726.6%	-83.7%	$24.55M	N/A	N/A	14
NXTC NextCure	2.7644 of 5 stars	$6.56 +15.5%	$19.00 +189.6%	-1.5%	$23.68M	N/A	N/A	40	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XCUR) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exicure (XCUR) Competitors

XCUR vs. BYSI, KYNB, ATOS, NXTC, and JSPR

How does Exicure compare to BeyondSpring?

Summary

How does Exicure compare to Kyntra Bio?

Summary

How does Exicure compare to Atossa Genetics?

Summary

How does Exicure compare to NextCure?

Summary

How does Exicure compare to Jasper Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exicure (XCUR) Competitors

XCUR vs. BYSI, KYNB, ATOS, NXTC, and JSPR

How does Exicure compare to BeyondSpring?

Do insiders & institutionals hold more shares of XCUR or BYSI?

Which has more volatility & risk, XCUR or BYSI?

Is XCUR or BYSI more profitable?

Does the media refer more to XCUR or BYSI?

Which has higher valuation and earnings, XCUR or BYSI?

Do analysts rate XCUR or BYSI?

Summary

How does Exicure compare to Kyntra Bio?

Is XCUR or KYNB more profitable?

Do analysts rate XCUR or KYNB?

Does the media refer more to XCUR or KYNB?

Which has more volatility and risk, XCUR or KYNB?

Which has preferable earnings & valuation, XCUR or KYNB?

Do insiders and institutionals hold more shares of XCUR or KYNB?

Summary

How does Exicure compare to Atossa Genetics?

Do analysts prefer ATOS or XCUR?

Which has stronger valuation & earnings, ATOS or XCUR?

Do insiders and institutionals have more ownership in ATOS or XCUR?

Which has more volatility & risk, ATOS or XCUR?

Is ATOS or XCUR more profitable?

Does the media prefer ATOS or XCUR?

Summary

How does Exicure compare to NextCure?

Is XCUR or NXTC more profitable?

Which has more risk and volatility, XCUR or NXTC?

Do analysts recommend XCUR or NXTC?

Which has stronger earnings & valuation, XCUR or NXTC?

Do insiders and institutionals believe in XCUR or NXTC?

Does the media favor XCUR or NXTC?

Summary

How does Exicure compare to Jasper Therapeutics?

Does the media refer more to XCUR or JSPR?

Which has more volatility and risk, XCUR or JSPR?

Is XCUR or JSPR more profitable?

Do analysts rate XCUR or JSPR?

Do insiders and institutionals have more ownership in XCUR or JSPR?

Which has stronger earnings & valuation, XCUR or JSPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools